Business
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad
About this update from Immuneering Corporation
[{"type":"text","content":"CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston. Details for the poster presentations are as follows: Title: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumorsDate: Thursday, October 12, 2023, 12:30 p.m. - 4:00 p.m. ETPoster session: Poster Session ALocation: Level 2, Exhibit Hall DAbstract number: A134 Title: Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivoDate: Thursday, October 12, 2023, 12:30 p.m. - 4:00 p.m. ETPoster session: Poster Session ALocation: Level 2, Exhibit Hall DAbstract number: A093 The abstracts will be available on the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics website. Following presentation, the posters will be available on the publications section of Immuneering’s website at https://immuneering.com/publications. About IMM-1-104 IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing. IMM-1-104 is currently being evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations for whom there are limited treatment options (NCT05585320). About IMM-6-415 IMM-6-415 targets RAF and RAS mutant tumors through deep cyclic inhibition of the MAPK pathway with an accelerated cadence. IMM-6-415 was designed with unique drug-like properties that distinguish it from other programs in the Immuneering pipeline, including a shorter half-life than IMM-1-104 which gives IMM-6-415 an accelerated cadence relative to the once-daily dosing of IMM-1-104. IMM-6-415 is being developed for monotherapy and combination applications in oncology, including the ability to enhance immune mediated ...